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 Table S1. Clinical characteristics of the Pakistani psoriasis cases 
Variable	  (unit)	   sample	  size	   mean	  ±	  standard	  error	  
male	  (%)	   351	   59.0	  ±	  2.6	  
age	  at	  exam	  (years)	   351	   35.4	  ±	  0.8	  
age	  at	  onset	  of	  psoriasis	  (years)	   349	   29.6	  ±	  0.7	  
family	  history	  (%)	   200	   28.0	  ±	  3.2	  
psoriatic	  arthritis	  (%)	   200	   4.0	  ±	  1.4	  
Table S2. Comparison of risk allele frequencies in Pakistan vs. population of disease locus discovery for 30 markers in 24 known 
psoriasis susceptility loci. 
 
	   	   	   Frequency	  of	  risk	  allele3	   	   	  
	   	   	   	   Discovery	  Population	   	   	  
Candidate	  Gene(s)	   Marker1	   Risk	  allele2	   Pakistan	   Europe	   China	   Japan	   	   P	  value
4	  
IL28RA	   rs4649203	   A	   0.6865	   0.7282	   —	   — 	   5.5E-­‐02	  
IL23R/STAT2	   rs2201841	   G	   0.5083	   0.2942	   — — 	   3.5E-­‐20	  
IL23R/STAT2	   rs11209026	   G	   0.9789	   0.9393	   — — 	   1.5E-­‐05	  
LCE3B/LCE3B	   LCE3C_LCE3B-­‐del	   del	   0.6430	   0.6486	   — — 	   7.2E-­‐01	  
REL	   rs702873	   G	   0.7528	   0.8443	   — — 	   1.7E-­‐06	  
IFIH1	   rs17716942	   A	   0.9453	   0.8443	   — — 	   1.1E-­‐12	  
ERAP1	   rs27524	   A	   0.4081	   0.3483	   — — 	   9.7E-­‐03	  
ERAP1	   rs151823	   A	   0.1498	   —	   0.4695	   — 	   9.0E-­‐35	  
IL13/IL4	   rs20541	   G	   0.6934	   0.7744	   — — 	   1.3E-­‐04	  
TNIP1	   rs17728338	   A	   0.1091	   0.0699	   — — 	   4.3E-­‐03	  
IL12B	  	   rs2082412	   G	   0.6865	   0.7770	   — — 	   1.7E-­‐05	  
IL12B	   rs3212227	   A	   0.6845	   0.2203	   — — 	   6.6E-­‐06	  
IL12B	   rs4379175	   C	   0.6888	   0.6570	   — — 	   1.6E-­‐01	  
PTTG1	   rs2431697	   C	   0.4505	   0.4195	   — — 	   2.0E-­‐01	  
HLA-­‐C	   7	  SNPs	   HLA-­‐Cw6	   0.1260	   0.0898	   — — 	   5.2E-­‐04	  
HLA-­‐C	   rs1131151	   HLA-­‐Cw1	   0.0290	   —	   — 0.1348	   	   6.1E-­‐08	  
TRAF3IP2	   rs33980500	   T	   0.0689	   0.0897	   — — 	   1.1E-­‐01	  
TNFAIP3	   rs610604	   G	   0.3241	   0.3259	   — — 	   9.6E-­‐01	  
DEFB4/DEFB103	   HSPD21	   +cn	   4.3322	   4.5058	   — — 	   5.5E-­‐02	  
CSMD1	   rs7007032	   C	   0.3906	   —	   0.2030	   — 	   6.4E-­‐12	  
CSMD1	   rs10088247	   C	   0.3230	   —	   0.2284	   — 	   1.6E-­‐04	  
IL23A	   rs2066807	   C	   0.9696	   0.9288	   —	   — 	   7.6E-­‐05	  
GJB2	   rs3751385	   T	   0.1322	   —	   0.4365	   — 	   2.0E-­‐33	  
NFKBIA	   rs12586317	   T	   0.7787	   0.7084	   —	   — 	   6.9E-­‐04	  
FBXL19	   rs10782001	   G	   0.6204	   0.3549	   —	   — 	   2.3E-­‐29	  
NOS2	   rs4795067	   G	   0.3870	   0.3575	   —	   — 	   2.0E-­‐01	  
SERPINB8	   rs514315	   T	   0.6409	   —	   0.7437	   — 	   1.7E-­‐04	  
TYK2	   rs12720356	   A	   0.9898	   0.8997	   —	   — 	   7.5E-­‐20	  
ZNF816A	   rs11084211	   G	   0.5975	   —	   0.6523	   — 	   6.0E-­‐02	  
RNF114	   rs495337	   C	   0.4490	   0.5950	   —	   — 	   6.9E-­‐10	  
1In addition to SNPs that are denoted by their dbSNP rsid, other markers listed include LCE3C_LCE3B-del, which is a deletion-
insertion of 32.2-kb segment encompassing LCE3C and LCE3B genes; HLA-Cw6, which is assayed by seven SNPs in exons 2 and 3 
of HLA-C (rs28732105, rs1050409, rs1131123, rs1131118, rs1050384, rs17839985, and rs41547419); HLA-Cw1, which is uniquely 
tagged by the A allele of SNP rs1131151 in exon 2 of HLA-C; and HSPD21, which is the PRT assay for the beta-defensin CNV 
described by Aldhous et al. (2010).  
2Determination of risk allele based on published reports, except for rs4379175, where the positively associated allele in the large 
Michigan case-control cohort is designated as risk. For HSPD21, an increase in copy number (+cn) is associated with increased risk 
of psoriasis, and mean copy numbers of the B-defensin CNV are shown instead of allele frequencies (mean computed after fitting of 
bias-corrected Gaussian mixed model to the distribution of raw copy number estimates). 
3 Risk allele frequencies in Pakistan were estimated from the 545 unaffected Pakistan controls in this study. For the populations where 
association of the marker with psoriasis was first discovered, estimates of risk allele frequency were estimated primarily from 
samples in phase 1 (version 3) of the 1000 Genomes project, namely 379 European (GBR, FIN, IBS, TSI), 197 Han Chinese (CHB, 
CHS), and 89 Japanese (JPT) samples. Risk allele frequencies of the LCE3C_LCE3B-del indel and HLA-Cw6, as well as copy 
number for the HSPD21 marker, were estimated from the 2,505 unaffected Michigan controls used in this study, which are all of 
European ancestry.  
4For all markers except the HSPD21 CNV, the nominal p-value is shown from a Fisher's exact test of the difference in risk allele 
frequency between Pakistanis and the discovery population. For HSPD21, the nominal p-value for a randomization version of a two 
sample t-test with pooled variance for the difference in mean copy number is shown. P-values are color coded: black font indicates a 
corresponding false discovery rate (FDR) > 0.05, cyan font indicates a corresponding FDR ≤ 0.05 and an absolute difference in allele 
frequency < 0.10, green font indicates a corresponding FDR ≤ 0.05 and an absolute difference in allele frequency of 0.10–0.20, and 
red font indicates an FDR ≤ 0.05 and an absolute difference in allele frequency > 0.20. 
	  
